DNLI

#1306

Denali Therapeutics Inc. Common Stock

21.1800

+0.21%

Сектор:

Базовая:

Валюта прибыли:

Дневной диапазон

Годовой диапазон

Дневное изменение

+0.21%

Месячное изменение

-1.17%

6-месячное изменение

+30.98%

Годовое изменение

+30.98%

Предыдущее закрытие

21.1350

Open

21.1850

Bid

Ask

Low

21.1800

High

21.1850

Объем

143

Open full chart

Financials

Overview Отчетность Statistics Dividends

Quarterly Annual

Cash from operating activities 416.15 M211.39 M244.72 M357.99 M347.69 M412.6 M 412.6 M Cash from investing activities 623.21 M21.63 M141.39 M249.31 M88.76 M255.28 M 255.28 M Cash from financing activities 634.75 M19.35 M310.67 M17.82 M484.3 M189.22 M 189.22 M Free cash flow 413.06 M202.89 M226.88 M345.05 M331.78 M403.1 M 403.1 M

DNLI

Financials

Новости

DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus

Wolfe Research присваивает акциям Denali Therapeutics рейтинг Peerperform

Wolfe Research initiates Denali Therapeutics stock with Peerperform

Denali Therapeutics Inc. (DNLI) Presents at 22nd Annual WORLDSymposium - Slideshow (NASDAQ:DNLI) 2026-02-06

Denali Therapeutics Inc. (DNLI) Shareholder/Analyst Call Transcript

Denali Therapeutics Inc. (DNLI) Shareholder/Analyst Call - Slideshow (NASDAQ:DNLI) 2026-02-05

5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates

Denali представит данные по терапии редких заболеваний на WORLDSymposium

Denali to present clinical data on rare disease therapies at WORLDSymposium

Акции Denali Therapeutics сохраняют рейтинг "Покупать" от Goldman Sachs

Denali Therapeutics stock maintains Buy rating at Goldman Sachs on pipeline progress

Denali Therapeutics Inc. (DNLI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript